Invesco Dynamic Pharmaceuticals ETF Price & Performance (PJP)

Several institutional investors modified their holdings in the Invesco Pharmaceuticals ETF during the fourth quarter, with LPL Financial reducing its stake by 6.1%. Other firms, including Raymond James and MGB Wealth Management, also reported changes. The ETF's stock recently opened at $74.59, marking a 4.2% decline.12

Recent performance data reveals the Invesco Pharmaceuticals ETF returned 9.07% over the past year, underperforming the S&P Composite 1500 Pharmaceuticals Index, which posted -0.35%. The ETF remains diversified, with top holdings in Abbott Laboratories, Johnson & Johnson, and Gilead Sciences, and a notable allocation to small- and large-cap stocks.34

The Invesco Pharmaceuticals ETF currently manages $231 million in assets and offers a 1.18% dividend yield. With a price-to-earnings ratio of 19.79 and 34 holdings, PJP continues to focus on U.S. pharmaceutical equities. The ETF’s one-year return stands at 2.56%, reflecting recent market volatility in the sector.25